Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures.
Mickaël J C HiligsmannStuart L SilvermanAndrea J SingerLeny PearmanYamei WangJohn CaminisJean-Yves ReginsterPublished in: Aging clinical and experimental research (2024)
Sequential therapy with ABL/ALN was cost-effective in US men and women at very high risk of fractures.
Keyphrases